5,980 Shares in Invesco Biotechnology & Genome ETF $PBE Acquired by Investment House LLC

Investment House LLC purchased a new position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 5,980 shares of the company’s stock, valued at approximately $582,000. Investment House LLC owned approximately 0.14% of Invesco Biotechnology & Genome ETF as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Royal Bank of Canada boosted its stake in shares of Invesco Biotechnology & Genome ETF by 25.9% in the 1st quarter. Royal Bank of Canada now owns 59,329 shares of the company’s stock valued at $4,698,000 after purchasing an additional 12,215 shares in the last quarter. Cetera Investment Advisers grew its holdings in shares of Invesco Biotechnology & Genome ETF by 2.0% during the 1st quarter. Cetera Investment Advisers now owns 23,139 shares of the company’s stock valued at $1,832,000 after purchasing an additional 464 shares during the last quarter. YHB Investment Advisors Inc. purchased a new position in Invesco Biotechnology & Genome ETF in the 3rd quarter worth $2,169,000. Envestnet Asset Management Inc. raised its position in Invesco Biotechnology & Genome ETF by 4.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 22,250 shares of the company’s stock worth $1,995,000 after purchasing an additional 888 shares during the period. Finally, Rockefeller Capital Management L.P. raised its position in Invesco Biotechnology & Genome ETF by 6.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,666 shares of the company’s stock worth $876,000 after purchasing an additional 666 shares during the period.

Invesco Biotechnology & Genome ETF Stock Down 0.7%

Invesco Biotechnology & Genome ETF stock opened at $98.72 on Friday. The company has a market capitalization of $428.44 million, a PE ratio of 20.44 and a beta of 0.70. The firm has a fifty day simple moving average of $96.49 and a two-hundred day simple moving average of $89.48. Invesco Biotechnology & Genome ETF has a twelve month low of $72.27 and a twelve month high of $99.99.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.